A detailed history of Great Lakes Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Great Lakes Advisors, LLC holds 20,370 shares of BMY stock, worth $1.18 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
20,370
Previous 19 107110.53%
Holding current value
$1.18 Million
Previous $0 Infinity%
% of portfolio
0.01%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$39.66 - $51.75 $807,120 - $1.05 Million
20,351 Added 107110.53%
20,370 $1.05 Million
Q2 2024

Aug 05, 2024

SELL
$40.25 - $52.99 $24.5 Million - $32.2 Million
-608,336 Reduced 100.0%
19 $0
Q1 2024

May 08, 2024

SELL
$47.98 - $54.4 $31.3 Million - $35.5 Million
-652,234 Reduced 51.74%
608,355 $33 Million
Q4 2023

Feb 08, 2024

SELL
$48.48 - $57.85 $22.2 Million - $26.5 Million
-457,616 Reduced 26.63%
1,260,589 $64.7 Million
Q3 2023

Nov 07, 2023

BUY
$57.89 - $64.73 $27.9 Million - $31.2 Million
482,199 Added 39.01%
1,718,205 $99.7 Million
Q2 2023

Aug 10, 2023

SELL
$63.71 - $70.74 $11.5 Million - $12.8 Million
-180,838 Reduced 12.76%
1,236,006 $79 Million
Q1 2023

May 10, 2023

BUY
$65.71 - $74.53 $89 Million - $101 Million
1,354,019 Added 2155.22%
1,416,844 $98.2 Million
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $3.84 Million - $4.55 Million
56,109 Added 835.45%
62,825 $4.52 Million
Q3 2022

Nov 09, 2022

BUY
$0.13 - $76.84 $374 - $221,606
2,884 Added 75.26%
6,716 $478,000
Q2 2022

Aug 09, 2022

BUY
$72.62 - $79.98 $15,177 - $16,715
209 Added 5.77%
3,832 $295,000
Q1 2022

May 06, 2022

SELL
$61.48 - $73.72 $88,223 - $105,788
-1,435 Reduced 28.37%
3,623 $265,000
Q4 2021

Feb 09, 2022

SELL
$53.63 - $62.52 $14,640 - $17,067
-273 Reduced 5.12%
5,058 $316,000
Q3 2021

Nov 09, 2021

SELL
$59.17 - $69.31 $28,697 - $33,615
-485 Reduced 8.34%
5,331 $315,000
Q2 2021

Aug 11, 2021

SELL
$61.91 - $67.42 $7,181 - $7,820
-116 Reduced 1.96%
5,816 $389,000
Q1 2021

May 03, 2021

BUY
$59.34 - $66.74 $6,824 - $7,675
115 Added 1.98%
5,932 $374,000
Q4 2020

Feb 09, 2021

BUY
$57.74 - $65.43 $15,705 - $17,796
272 Added 4.91%
5,817 $360,000
Q3 2020

Nov 04, 2020

SELL
$57.43 - $63.64 $7,523 - $8,336
-131 Reduced 2.31%
5,545 $334,000
Q2 2020

Aug 07, 2020

BUY
$54.82 - $64.09 $39,634 - $46,337
723 Added 14.6%
5,676 $333,000
Q1 2020

May 08, 2020

SELL
$46.4 - $67.43 $201,144 - $292,309
-4,335 Reduced 46.67%
4,953 $276,000
Q4 2019

Feb 07, 2020

BUY
$49.21 - $64.19 $113,429 - $147,957
2,305 Added 33.01%
9,288 $596,000
Q3 2019

Nov 06, 2019

SELL
$42.77 - $50.71 $89,902 - $106,592
-2,102 Reduced 23.14%
6,983 $354,000
Q2 2019

Aug 05, 2019

SELL
$44.62 - $49.34 $400,241 - $442,579
-8,970 Reduced 49.68%
9,085 $412,000
Q1 2019

May 07, 2019

SELL
$45.12 - $53.8 $2.54 Million - $3.03 Million
-56,256 Reduced 75.7%
18,055 $861,000
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $1.23 Million - $1.6 Million
-25,301 Reduced 25.4%
74,311 $3.86 Million
Q3 2018

Nov 30, 2018

BUY
$55.19 - $62.25 $942,369 - $1.06 Million
17,075 Added 20.69%
99,612 $6.18 Million
Q3 2018

Nov 15, 2018

SELL
$55.19 - $62.25 $436,718 - $492,584
-7,913 Reduced 8.75%
82,537 $5.12 Million
Q2 2018

Aug 13, 2018

SELL
$50.53 - $62.98 $3.63 Million - $4.52 Million
-71,792 Reduced 44.25%
90,450 $5.01 Million
Q1 2018

May 07, 2018

SELL
$59.92 - $68.98 $4.3 Million - $4.95 Million
-71,727 Reduced 30.66%
162,242 $10.3 Million
Q4 2017

Feb 08, 2018

SELL
$59.94 - $65.35 $891,008 - $971,427
-14,865 Reduced 5.97%
233,969 $14.3 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $13.7 Million - $15.9 Million
248,834
248,834 $15.9 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Great Lakes Advisors, LLC Portfolio

Follow Great Lakes Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Lakes Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Lakes Advisors, LLC with notifications on news.